Vanderbilt Doctor Blames Tennessee Congressman For Being Pulled Into Fetal Tissue Probe | Nashville Public Radio

Vanderbilt Doctor Blames Tennessee Congressman For Being Pulled Into Fetal Tissue Probe

Oct 25, 2016

A video that purported to show Planned Parenthood selling fetal tissue has been discredited. But it spawned an inquiry that carries on, led by Congressman Marsha Blackburn.

Her investigative panel has been forcing researchers to turn over emails and billing information. They're trying to root out people who may have profited from the sale of fetal parts, which is illegal.

Vanderbilt surgical resident Eugene Gu received one of those subpoenas. After months of laying low, Gu is now speaking out, like this appearance on Science Friday. and this article in Nature. He says he broke no law.

"These are tissues that would normally be thrown away into the garbage can, into the medical incinerator," he says. "Fetal tissue researchers like myself do not promote abortion in any way."

Gu started a company called Ganogen Inc., which acquires fetal tissue from Planned Parenthood through a middleman named StemExpress. Gu says no one ever made money on the endeavor, though funds did change hands. He says payments were just to pay for packaging and shipping the sensitive material. Gu has since converted his company into a nonprofit called the Ganogen Research Institute.

While Gu says no one profited from the fetal tissue, he does say it has been invaluable, scientifically. His firm successfully transplanted fetal kidneys and a heart into a rat. The video was uploaded on Youtube.

The hope is to grow organs that could be used in humans. Gu says he understands that his research will always be divisive.

"I can see why someone would find that disturbing. It's a very visceral reaction to see the human heart beating inside an animal," Gu says. "I want to be sensitive to people who think it's jarring. What I can say is, a lot of things we do in the operating room can be jarring to people. But they save lives."

Gu hopes to offer a new avenue for organ donation. But what if the research is wildly successful?

"The thing is, there are far more abortions that occur than there are patients on the transplant waiting list," he says. "There's never going to be an incentive or demand to get more abortions."

A spokesman for Blackburn's investigative panel argues that "no serious scientists are pursuing this line of research as a method of addressing the shortage of organs available for transplant."

But as long as there is fetal tissue available, Gu says he plans to continue his research, even if doing so puts him at odds with abortion opponents.